Description
Medical Uses: Pylarify is a radioactive diagnostic agent used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in males with prostate cancer:
- With suspected metastasis who are candidates for initial definitive therapy.
- With suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels.
Recommended Dosage: Pylarify is a radioactive medication. It should be received, used, and administered only by authorized personnel qualified by training and experience. Appropriate safety measures should be implemented to minimize radiation exposure during administration. This includes the use of waterproof gloves and appropriate radiation shielding, such as syringe shields, when preparing and handling the injection.
The recommended activity for PET imaging is 333 MBq (9 mCi), with an acceptable range of 296 to 370 MBq (8 to 10 mCi), administered as a single bolus intravenous injection. Imaging should begin approximately 60 minutes after the administration of Pylarify. Patients should void their bladder before starting the imaging. Image acquisition should start from the mid-thigh and proceed to the skull vertex.
Reviews